Nisa Investment Advisors LLC Sells 2,484 Shares of Alnylam Pharmaceuticals, Inc. $ALNY

Nisa Investment Advisors LLC lessened its stake in Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) by 20.5% in the fourth quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 9,649 shares of the biopharmaceutical company’s stock after selling 2,484 shares during the period. Nisa Investment Advisors LLC’s holdings in Alnylam Pharmaceuticals were worth $3,837,000 at the end of the most recent reporting period.

A number of other institutional investors have also recently made changes to their positions in ALNY. Thematics Asset Management bought a new stake in Alnylam Pharmaceuticals during the second quarter worth about $1,995,000. Mediolanum International Funds Ltd purchased a new position in shares of Alnylam Pharmaceuticals in the 3rd quarter worth about $11,389,000. Rakuten Investment Management Inc. bought a new position in shares of Alnylam Pharmaceuticals during the 3rd quarter valued at about $14,205,000. Generali Asset Management SPA SGR increased its position in shares of Alnylam Pharmaceuticals by 6,368.0% during the 3rd quarter. Generali Asset Management SPA SGR now owns 3,234 shares of the biopharmaceutical company’s stock valued at $1,475,000 after purchasing an additional 3,184 shares during the last quarter. Finally, Investment Management Corp of Ontario raised its holdings in shares of Alnylam Pharmaceuticals by 35.4% during the 2nd quarter. Investment Management Corp of Ontario now owns 31,521 shares of the biopharmaceutical company’s stock valued at $10,279,000 after buying an additional 8,244 shares in the last quarter. Institutional investors own 92.97% of the company’s stock.

Alnylam Pharmaceuticals Stock Down 3.0%

Shares of Alnylam Pharmaceuticals stock opened at $318.85 on Friday. The company has a current ratio of 2.76, a quick ratio of 2.71 and a debt-to-equity ratio of 1.28. Alnylam Pharmaceuticals, Inc. has a 12-month low of $205.87 and a 12-month high of $495.55. The company has a market cap of $42.29 billion, a P/E ratio of 186.46 and a beta of 0.39. The company’s fifty day simple moving average is $327.55 and its two-hundred day simple moving average is $396.63.

Alnylam Pharmaceuticals (NASDAQ:ALNY) last announced its earnings results on Thursday, February 12th. The biopharmaceutical company reported $1.25 earnings per share for the quarter, missing analysts’ consensus estimates of $1.43 by ($0.18). Alnylam Pharmaceuticals had a net margin of 6.43% and a return on equity of 69.02%. The company had revenue of $1.10 billion for the quarter, compared to the consensus estimate of $1.16 billion. During the same period in the previous year, the firm posted ($0.65) EPS. The company’s revenue for the quarter was up 84.9% on a year-over-year basis. Research analysts anticipate that Alnylam Pharmaceuticals, Inc. will post -1.7 EPS for the current year.

Wall Street Analyst Weigh In

ALNY has been the subject of several research reports. Barclays began coverage on Alnylam Pharmaceuticals in a research note on Wednesday, January 28th. They issued an “overweight” rating and a $527.00 target price for the company. Truist Financial decreased their price target on shares of Alnylam Pharmaceuticals from $535.00 to $530.00 and set a “buy” rating on the stock in a research note on Thursday, January 8th. Jefferies Financial Group restated a “hold” rating and issued a $330.00 price objective (down from $522.00) on shares of Alnylam Pharmaceuticals in a report on Monday, March 16th. Bank of America reaffirmed a “buy” rating on shares of Alnylam Pharmaceuticals in a report on Thursday, February 12th. Finally, Oppenheimer began coverage on shares of Alnylam Pharmaceuticals in a research report on Wednesday, January 7th. They issued an “outperform” rating and a $500.00 target price on the stock. One analyst has rated the stock with a Strong Buy rating, nineteen have assigned a Buy rating and six have issued a Hold rating to the company’s stock. Based on data from MarketBeat.com, the company has a consensus rating of “Moderate Buy” and a consensus target price of $473.87.

Insiders Place Their Bets

In other news, EVP Tolga Tanguler sold 1,598 shares of the stock in a transaction that occurred on Monday, March 2nd. The stock was sold at an average price of $327.65, for a total value of $523,584.70. Following the completion of the transaction, the executive vice president owned 36,606 shares of the company’s stock, valued at approximately $11,993,955.90. This represents a 4.18% decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. Also, CEO Yvonne Greenstreet sold 6,799 shares of the firm’s stock in a transaction that occurred on Monday, March 2nd. The shares were sold at an average price of $327.65, for a total value of $2,227,692.35. Following the completion of the transaction, the chief executive officer owned 98,628 shares of the company’s stock, valued at approximately $32,315,464.20. The trade was a 6.45% decrease in their position. The SEC filing for this sale provides additional information. Insiders sold a total of 53,923 shares of company stock valued at $18,072,087 over the last ninety days. 1.50% of the stock is owned by corporate insiders.

Alnylam Pharmaceuticals Company Profile

Alnylam Pharmaceuticals, Inc (NASDAQ: ALNY) is a biopharmaceutical company focused on the discovery, development and commercialization of RNA interference (RNAi) therapeutics. Founded to translate the scientific discovery of RNAi into new medicines, Alnylam applies small interfering RNA (siRNA) technology to silence disease-causing genes. The company develops therapies designed to provide durable disease modification by targeting underlying genetic drivers across a range of rare and more prevalent conditions.

Alnylam has advanced multiple siRNA-based products into commercialization, initially using lipid nanoparticle delivery and more recently employing GalNAc-conjugate chemistry to enable targeted delivery to the liver with subcutaneous dosing.